<DOC>
	<DOC>NCT01488331</DOC>
	<brief_summary>This prospective, multi-center, observational study will assess the progression-free survival and safety of patients with locally advanced or metastatic non-small cell lung cancer treated with Tarceva (erlotinib) and not disease progressing after at least 9 months. Data will be collected for 24 months.</brief_summary>
	<brief_title>An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Diagnosis of locally advanced or metastatic nonsmall cell lung cancer (NSCLC, stage III/IV) Treatment with Tarceva monotherapy and not progressing after at least 9 months at the date of study start Not agreeing to be followedup (for a maximum of 24 months)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>